CME Dinner Symposium
IN ASSOCIATION WITH THE 17th WCIRDC

EPA–Icosapent Ethyl Role in Clinical Practice

Wednesday December 4, 2019
7:30 pm – 9:30 pm
Hilton Universal City Hotel
Los Angeles, CA

This is a CME Symposium Supported by an Educational Grant from Amarin
Free for all 17th WCIRDC Attendees | Register Online: wcir.org/registration
Dinner attendance is limited! Please e-mail jeannine@tmioa.com to pre-register for this program.

EARN
CME ACCME CREDIT
2.00

IN ASSOCIATION WITH THE

This is a CME Symposium Supported by an Educational Grant from Amarin
Free for all 17th WCIRDC Attendees | Register Online: wcir.org/registration
Dinner attendance is limited! Please e-mail jeannine@tmioa.com to pre-register for this program.

EARN
CME ACCME CREDIT
2.00
EPA – Icosapent Ethyl – Role in Clinical Practice

Program Description
The Omega-3 EPA — icosapent ethyl — has been approved over several years to manage severe hypertriglyceridemia (>500 mg/dL). A recent landmark trial with icosapent ethyl — REDUCE-IT — revealed a remarkable reduction in CV morbidity and mortality in patients with established cardiovascular disease who were maximally treated with standard of care. The outcome persisted as primary prevention in patients with diabetes and at least one CV risk factor and no prior events. Although there are proposed suggestions about the mechanism of action of EPA — icosapent ethyl — to explain the CV outcome, the study results did not reveal a specific parameter which would explain the outcome. Following the publication of the study, clinicians are facing several gaps of knowledge. Particularly, many clinicians do not know and understand the results. For those who do know, they have difficulties applying it in practice. Specifically, many of the so-called “REDUCE-IT” patients would also be eligible for other medications that have outcome results in reducing CVD. Physicians need better guidance on choosing the appropriate patient to prescribe EPA — icosapent ethyl — as compared to the other available agents. In other words, what should the patient characteristics be to make EPA — icosapent ethyl — the preferred agent? The goal of this CME program is to identify those patient characteristics that would make EPA — icosapent ethyl — the preferred agent.

Learning Objectives
Upon completion of this symposium, participants should be able to:
- Know and understand the results of REDUCE-IT
- Be aware of the economic impact of prescribing EPA — icosapent ethyl
- Explain the role of contemporary guidelines in preventing ASCVD in patients
- Identify the appropriate patient where EPA — icosapent ethyl — would be preferred both in primary and secondary prevention

Target Audience
This educational initiative is designed for cardiologists, lipidologists, endocrinologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, nurse practitioners, physician assistants, dieticians, diabetes educators and all other healthcare professionals interested in the pathophysiology, prevention and treatment of cardiovascular disease, diabetes and associated conditions, as well as the effect of these conditions on health and society.

FACULTY 2019

Michael Miller, MD, FACC, FAHA Chair
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Staff Physician, Baltimore VA Medical Center
Chair, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, Maryland

James A. Underberg, MD, MS, FACP, FNYAM, FASPC, FNLA
Clinical Assistant Professor of Medicine
Lipidology & Cardiovascular Disease Prevention
NYU Medical School & Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
Past-President National Lipid Association
New York, NY 10022

Sergio Fazio, MD, PhD
The William and Sonja Comar Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Michael Miller, MD, FACC, FAHA Chair
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Staff Physician, Baltimore VA Medical Center
Chair, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, Maryland

Yehuda Handelsman, MD
FACP, FNLA, MACE Chair
Medical Director & Principal Investigator, Metabolic Institute of America
Chair & Program Director, WCRDC
Tarzana, California

Aruna Pradhan, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Physician
Brigham and Women’s Hospital
Department of Medicine, Preventive Medicine
Boston, MA

William S. Weintraub, MD, MACC
FACP, FASE, FESC
Chair
Director of Outcomes Research
MedStar Washington Hospital Center
Washington, District of Columbia

Yehuda Handelsman, MD
FACP, FNLA, MACE Chair
Medical Director & Principal Investigator, Metabolic Institute of America
Chair & Program Director, WCRDC
Tarzana, California

Sergio Fazio, MD, PhD
The William and Sonja Comar Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

William S. Weintraub, MD, MACC
FACP, FASE, FESC
Chair
Director of Outcomes Research
MedStar Washington Hospital Center
Washington, District of Columbia

Aruna Pradhan, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Physician
Brigham and Women’s Hospital
Department of Medicine, Preventive Medicine
Boston, MA

CME Dinner Symposium
Free for 17th WCIRDC Attendees  |  Learn more at www.wcir.org/CMEdinner

Dinner attendance is limited! If you are already registered for the 17th WCIRDC, please email Jeannine@tmioa.com to pre-register for this symposium.

To register for the entire 17th WCIRDC, which includes this CME Dinner Symposium, please visit www.wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc. designates this live educational activity for a maximum of 2 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@tmioa.com or 818.342.1889

This is a CME Program Supported by an Educational Grant from Amarin